By Benjamin Chiou
Date: Monday 23 Feb 2026
(Sharecast News) - Eli Lilly & Co on Monday unveiled a new multi-dose form of its blockbuster obesity drug Zepbound, allowing patients to receive a months' worth of doses in a single pen.
Shares were up 3.6% at $1,046.06 in early deals on Wall Street, supported by the news that Novo...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news